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S-allylcysteine Improves Blood Flow
Recovery and Prevents Ischemic Injury
by Augmenting Neovasculogenesis
Jia-Ning Syu1, Mei-Due Yang2,3,4, Shu-Yao Tsai5,
En-Pei Isabel Chiang6, Shao-Chih Chiu7,8, Che-Yi Chao5,9,
Raymond L. Rodriguez10, and Feng-Yao Tang1
Abstract
Studies suggest that a low level of circulating human endothelial progenitor cells (EPCs) is a risk factor for ischemic injury and
coronary artery disease (CAD). Consumption of S-allylcysteine (SAC) is known to prevent CAD. However, the protective
effects of SAC on the ischemic injury are not yet clear. In this study, we examined whether SAC could improve blood flow
recovery in ischemic tissues through EPC-mediated neovasculogenesis. The results demonstrate that SAC significantly
enhances the neovasculogenesis of EPCs in vitro. The molecular mechanisms for SAC enhancement of neovasculogenesis
include the activation of Akt/endothelial nitric oxide synthase signaling cascades. SAC increased the expression of c-kit,
b-catenin, cyclin D1, and Cyclin-dependent kinase 4 (CDK4) proteins in EPCs. Daily intake of SAC at dosages of 0.2 and 2
mg/kg body weight significantly enhanced c-kit protein levels in vivo. We conclude that dietary consumption of SAC improves
blood flow recovery and prevents ischemic injury by inducing neovasculogenesis in experimental models.
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Introduction
Coronary artery disease (CAD) and ischemic stroke are
the most common causes of death in individuals with
cardiovascular disease (CVD) worldwide.1,2 Due to the
endothelial dysfunction, critical limb ischemia (CLI) is
a major risk factor for CAD and stroke.3 Therefore, revas-
cularization of ischemic injuries plays a key role in the
tissue repair process.4
Previous studies have shown hematopoietic endothelial
progenitor cells (EPCs) derived from bone marrow (BM)
comprise a provasculogenic subpopulation of hematopoietic
stem cells (HSCs).5–8 EPCs are able to induce revasculariza-
tion of ischemic injuries and facilitate tissue regenera-
tion.9,10 Therefore, these circulating EPCs are believed to
prevent ischemic injuries such as CAD and stroke with their
potential for neovascularization.11 These human hemato-
poietic EPCs and HSCs are characterized by cell surface
markers, including CD 34, CD133, CD105 (endoglin), and
CD309 (Flk-1/KDR). In mice, hematopoietic EPCs and
HSCs bear membrane receptors such as c-kit, Sca-1,
CD34, and Flk-1.12,13 These circulating BM-derived EPCs
engraft easily, migrating into the injured tissues following
ischemia, initiating neovasculogenesis, and participating
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vascular repair.14,15 This insight may lead to discoveries of
EPC applications that are helpful in the prevention and treat-
ment of many diseases.13 This assumption is supported by a
study that demonstrated therapeutic neovascularization in
ischemic tissues was induced by the transplantation of
EPCs.16,17 A clinical study showed that a reduced circulating
peripheral level of EPCs is a risk factor for both CAD and
stroke.18 Strong correlations were also reportedly found
between the severity of atherosclerotic stress and EPC lev-
els.19 With a cooperation of different types in many tissues,
EPCs participate in the turnover of healthy and damaged
endothelium in a variety of different tissues, maintaining
regenerative and reparative potential, thereby playing an
important role in delaying the development of atherosclero-
sis and CVD.8 This suggests that an increasing level of EPCs
provides a mean for lowering the risk of ischemic injuries
and CAD through the induction of neovascularization.20,21
Unlike neovasculogenesis, adult angiogenesis is the for-
mation of new blood vessels from preexisting ones, a process
that requires the proliferation and migration of human micro-
vascular endothelial cells (ECs).22 It is known that the
growth of human ECs from capillary vessels contributes to
postnatal angiogenesis in many physiological and patholo-
gical conditions.23,24 However, these mature ECs are term-
inally differentiated and exhibit a low level of differentiation
potential.25 Therefore, these adult ECs may have reduced
capacity for the repair of damaged tissues.
Stem cell factor (SCF), a cellular mitogen, induces cell
migration and neovasculogenesis.25,26 It has been sug-
gested that c-kit protein, a receptor for SCF, is important
for the blood vessel formation of EPCs.25 For this reason,
the c-kit receptor protein and downstream signaling mole-
cules have attracted considerable attention for their ability
to regulate neovasculogenesis.27 Recent studies have sug-
gested that SCF induces neovasculogenesis through the
downstream c-kit protein and Akt signaling pathway in
EPCs.25,28,29 This suggests a connection between the PI3-
K/Akt signaling pathways and the increased capacity of
EPCs to promote neovasculogenesis.30 Results have also
demonstrated the crucial function of Akt signaling in the
migration and proliferation of EPCs.29 Previous study indi-
cated that Akt is required for the activation of the down-
stream endothelial nitric oxide synthase (eNOS), which
increases the migration capacity in EPCs.31 It is also well
known that the phosphorylation of the Akt protein enhances
cell proliferation through phosphorylation of GSK-3b and
increased levels of the cyclin D1 protein.32
Due to the augmentation of neovasculogenesis by dietary
approaches, EPCs have attracted considerable interest from
biomedical researchers and nutritional scientists. Epidemiolo-
gical studies have reported an inverse correlation between the
consumption of organosulfur compound–containing vegeta-
bles and the incidence of CAD.33 The best known organosulfur
compounds associated with CAD protection are contained in
garlic.34 The organosulfur compounds in garlic that appear to
be most cardioprotective are diallyl disulfide (DADS), diallyl
trisulfide (DATS), and S-allylcysteine (SAC).35 Compared to
DADS and DATS, SAC is the most abundant organosulfide
in the hydrophilic fraction of aged garlic extract
(AGE).35,36 Many studies have shown that the intake of
garlic components reduces the risk of CAD.34 Other studies
have reported that garlic consumption is associated with a
reduced prevalence of ischemic injuries37,38 and that intake
of AGE lowers the risk of CAD and stroke.33,39 SAC
increases nitric oxide (NO) bioavailability and enhances
endothelial function through its antioxidant effects.40 It has
been reported that SAC consumption effectively prevents
ischemic myocardium and chronic diseases such as CAD due
to its anti-inflammatory and antioxidant effects.40
Our previous study on the oleophilic constituents of garlic
extract suggested that DADS and DATS significantly
induced neovasculogenesis in EPCs.38 However, compara-
ble preclinical studies of the neovasculogenesis and
ischemia-protective properties of SAC in EPCs were not
available. Therefore, the current study investigates the appli-
cation of SAC for the simulation of neovasculogenesis and
its impact on ischemic injury prevention in both in vitro and
in vivo models.
Materials and Methods
Reagents
The Endothelial Cell Growth Medium-2 (EGM-2) growth kit
was obtained from Lonza, Inc. (Allendale, NJ, USA). Fetal
bovine serum (FBS) and protein extraction kit (Nuclear and
Cytoplasmic Extraction Reagents [NE-PER] extraction kit)
were purchased from Thermo Fisher Scientific, Inc. (Pitts-
burgh, PA, USA) and Pierce Biotechnology Inc. (Lackford,
IL, USA), respectively. Antiactin antibody, SAC (purity >
99%), L-NG-Nitroarginine methyl ester (L-NAME) (a spe-
cific inhibitor of eNOS), and wortmannin (a specific inhibi-
tor of PI3-K) were obtained from Sigma, Inc. (St Louis, MO,
USA). Immun-Blot Polyvinylidene difluoride (PVDF) mem-
brane was purchased from BioRad (Hercules, CA, USA).
Anticyclin D1 monoclonal antibody, Matrigel1, stem cell
factor (SCF), and collagen were purchased from BD
Bioscience, Inc. (San Jose, CA, USA). Other monoclonal
antibodies were from Cell Signaling Technology, Inc. (Dan-
vers, MA, USA). These antibodies were cross-reactive with
phospho-Akt (p-Akt; T308), total-Akt (t-Akt), phospho-
eNOS (p-eNOS; S1177), total-eNOS (t-eNOS), phospho-
GSK-3b (p-GSK-3b;S9), total-GSK-3b (t-GSK-3b), b-catenin,
c-kit, CDK4, histone H3, and lamin A proteins, respectively.
Preparation of Human EPCs
All protocols conformed to the ethical guidelines of the 1975
Declaration of Helsinki in a prior approval by the institu-
tional review board of the China Medical University Hospi-
tal. Human EPCs were generated from fresh human
umbilical cord blood mononuclear cells (MNC) as described
previously.41 Human EPCs produced from the method exert
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a highly proliferative potential.42 In brief, MNCs were iso-
lated by using Ficoll-Paque procedure. Colonies of EPCs
were featured with cobblestone shape while culturing
between 5 and 22 d. EPC colonies were selected and cultured
in 10% FBS MCDB-131 with an EGM-2 growth kit in a
collagen-coated tissue culture dish. Immunophenotyping of
EPCs was analyzed by fluorescence-activated cell sorting
(FACS; Becton Dickinson, San Diego, CA; Fig. 1A). We
used primary monoclonal antibodies against human CD31
conjugated to phycoerythrin (PE; all BD PharMingen, San
Diego, CA, unless otherwise indicated), human CD34 con-
jugated to PE, human CD105 conjugated to PE, human
CD166 conjugated to PE, human CD309 conjugated to
PE, and human CD45 conjugated to fluorescein isothiocya-
nate (FITC). EPCs used in this study were between passage
6 and 9.
Fig. 1. S-allylcysteine (SAC) effectively induces neovasculogenesis of endothelial progenitor cells (EPCs) in vitro. Characterization of
EPC-specific cell surface antigens by flow cytometry analysis (A). EPCs were in the condition of stem cell factor (2, 10, and 20 ng/mL) or
SAC (at concentrations of 10, 100, and 250 mM) for 8 h until the analysis of neovascularization (B). The values, mean+ standard deviation,
were represented as neovasculogenesis index (folds of tube formation in comparison with the untreated control subgroup) in 8 randomly
selected fields of each culture dish. Results of each subgroup were measured in triplicate and repeated twice. A different letter indicates a
statistically significant difference among different subgroups (P < 0.05).
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Cell Culture and Treatment of SAC
A stock SAC solution was prepared in ddH2O at a concentra-
tion of 400mM.HumanEPCs cultured in complete, antibiotic-
free MCDB-131 medium with 10% heat-inactivated FBS,
2 mM L-glutamine, and 1.5 g/L sodium bicarbonate in tissue
culture dishes coated with type I collagen (50 mg/mL). The
EPCmonolayers were incubated with SAC at various concen-
trations (0, 10, 100, and 250 mM) at 1 or 8 h time points.
Assessment of Cell Proliferation
The 3-[4,5-Dimethhylthiaoly]-2,5-diphenyltetrazolium bro-
mide (MTT) assay was performed to detect the cell prolifera-
tion. EPCs were seeded in 24-well plates, each well
containing 1  105 cells. The culture medium was replaced
by media in which there were SAC in the presence or absence
of different inhibitors for 6 h, respectively. There were tripli-
cate tests for each inhibitor. At the end of the experiment, one
of the plates was taken out and freshMTT (final concentration
0.5 mg/mL in PBS) was added to each well. After 2 h incuba-
tion, the culture media were discarded, 200 mL of acidic iso-
propanol were added to each well and vibrated to dissolve the
depositor. The optical density was measured at 570 nm with a
microplate reader (Tecan, Ma¨nnedorf, Switzerland).
Protein Extraction and Western Blotting Analysis
Protein extraction was prepared by using an NE-PER com-
mercial kit with inhibitors against protease and phosphatase.
Cell cultures were centrifuged for 10 min at 12,000 g to
separate the supernatant fraction (cytoplasmic extract) from
the remaining nuclear proteins. There was no contamination
between the cytoplasmic and nuclear fractions. Cytoplasmic
proteins (60 mg) were fractioned using 10% sodium-dodecyl
sulfate polyacrylamide gel electrophoresis and transferred to
a PVDF membrane. After the protein separation, PVDF
membrane was blotted with specific antibodies against target
protein such as c-kit. The blots were washed and reprobed
with antibody against internal control actin protein. The
remaining proteins such as p-Akt (T308), p-GSK-3b (S9),
p-eNOS(S1177), t-Akt, t-GSK-3b, and t-eNOS in cell
extracts were detected using protocols similar to those pre-
viously described.29 The corresponding t-Akt, t-GSK-3b, and
t-eNOS proteins were used as loading controls for p-Akt
(T308), p-GSK-3b (S9), and p-eNOS(S1177) proteins, respec-
tively. Actin was used as an internal control for the expression
of cytoplasmic proteins. Histone H3 was used as a negative
internal control for the expression of cytoplasmic proteins.
Nuclear proteins (60 mg) were also measured using the
same process. After transferring the protein to the PVDF
membrane, the membrane was blotted using a monoclonal
antibody against target b-catenin. The blots were stripped
and reprobed with internal control Lamin A antibody.
Nuclear cyclinD1 and CDK4 proteins were measured using
the same procedure.
Neovascularization Assay
Fifty microliter aliquots ofMatrigel (4 mg/mL) were placed in
96-well cell culture plates until gelatinization at 37 C. For the
neovascularization assay, EPCs were cultured in the presence
or absence of SAC in 96-well plates (1 104 cells/well) using
complete MCDB-131 medium. To examine the molecular
mechanisms of action, EPCs were cultured in the presence
or absence of SAC in the presence of signaling pathway inhi-
bitors including wortamannin, PD098059, or L-NAME. After
seeding in cell culture plates for 8 h, images of neovasculo-
genesis in EPCs were documented under an inverted
phase-contrast microscopy at a magnification of 40 with
an Olympus Imaging System (Tokyo, Japan) and analyzed
by using National Institutes of Health (NIH)-image analyzer
software program (Scion Corp., Frederick, MD, USA). Neo-
vascularization index was defined as the ratio of total length
of neovascularization in various subgroup to the one in control
subgroup.
Xenograft Implantation of EPCs
The animal protocol was reviewed and approved by an ethics
committee and the Institutional Animal Care and Use
Committee (IACUC) at China Medical University (animal
protocol no. 101-134-N). Female adult BALB/cAnN.Cg-
Foxn1nu/CrlNarl (BALB/c) AnN-Foxn1 immunodeficient
nude mice (18 to 23 g) approximately 3 to 4 wk old were
obtained from the National Laboratory Animal Center (Tai-
pei, Taiwan). Mice were kept in a specific pathogen-free
facility in accordance with standard regulations and princi-
ples. A neovasculogenesis xenograft model in experimental
mice was created by subcutaneous injection of EPCs (3 
106 EPCs/ per mouse) in phosphate buffer saline (PBS) and
Matrigel (0.15 mL) in each BALB/c nude mouse. After
inoculation of the EPCs, these experimental mice were
divided into 4 subgroups (N ¼ 4), and 5 mice per subgroup
(n ¼ 5). During the entire period of the experiment, the mice
were fed an AIN-93 M diet. The positive control group had
an injection of EPCs with a Matrigel mixture and SCF (20
ng/mL). In the negative control group, mice were injected
with a mixture of Matrigel and EPCs only. SAC was dis-
solved in ddH2O and stored in the freezer at 0 C. For the
experimental groups, SAC was provided to mice by gavage
feeding at a dosage of 0.2 or 2 mg/kg of body weight (BW)
per day after inoculation with EPCs. These experimental
mice were sacrificed after being euthanized with CO2 inha-
lation at the end of second week. The Matrigel inoculated for
neovascularization was detached from the nude mice for
further investigation.
Mouse Ischemic Hind-limb Model
Nine-week old female C57BL mice (n ¼ 6 per subgroup)
were randomly distributed into 3 subgroups (N ¼ 3): the
control subgroup receiving ddH2O only and experimental
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low SAC or high SAC subgroup receiving SAC (at 0.2 or 2
mg/kg of BW per day) by gavage feeding. A microsurgery
of the hind-limb ischemia model was performed by a
removal of the left femoral artery according to the previous
protocol.43 Images of blood recovery were documented
with a Laser Doppler Perfusion (LDP) imaging system after
the surgery and then documented daily. After completion of
image monitoring, the mice were sacrificed at the end of
second week. The ischemic limb tissues were removed
from mice and frozen immediately.
Histopathological, Immunohistochemical, and
Immunofluorescent Staining of Neovasculogenesis
Frozen liver tissues were cut in 5-mm sections and immedi-
ately fixed with 4% paraformaldehyde. Sections were
stained with Meyer’s hematoxylin–eosin staining for light
microscopy. Liver tissues were examined in a blinded man-
ner per tissue section and documented at 200 magnifica-
tion in any of the mice receiving SCF (20 ng/mL) or SAC
(either 0.2 or 2 mg/kg of BW).
For immunohistochemistry analysis, frozen tissue section
was treated with 0.3% H2O2 to inactivate the intrinsic per-
oxidase. Nonspecific protein reaction was suppressed with
10% normal serum for 1 h. Frozen tissue sections were fur-
ther incubated with specific antibody (at 1:300 ratio dilution)
against target protein such as c-kit. After the antibody incu-
bation, tissue sections were rinsed with PBS and treated with
biotinyated immunoglobin G at room temperature for 1 h.
The final reaction was completed by staining with avidin–
biotin complex reagent, diaminobenzidine, and H2O2.
For immunostaining, frozen tissues were sectioned and
probed with specific antibodies against target proteins such as
c-kit and VE-cadherin. The sectioned tissues treated with
anti-VE-cadherin primary antibody were then exposed to a
secondary antibody with an FITC. Other sectioned tissues
against anti-c-kit antibody were probed with a TxRd-labeled
secondary antibody. The location of nuclei in these sectioned
tissueswas determined by stainingwith 4,6-diamidino-2-phenyl
indole. Imaging was performed at 600 magnification. All
images were documented with an Olympus BX-51 microscope
using an Olympus imaging system at 200 magnification.
Statistical Analysis
SYSTAT biostatistic software, Version 11 (Chicago, IL,
USA) was used to determine the differences between the
experimental (SAC treatment) and control groups of EPCs.
Statistical difference in the levels of neovasculogenesis is
required to reject the null hypothesis of no difference
between the mean values from experimental and control
subgroups by using 1-way analysis of variance. A Duncan’s
multiple range test was used to evaluate differences among
different subgroups. For the analysis of Western blotting
results, a statistical difference between control and
experimental subgroups was examined using the Student’s
t-test at the P ¼ 0.05 significance level.
Results
SAC Effectively Induces Neovasculogenesis of EPCs
In Vitro
To investigate the in vitro neovasculogenic effects of SAC in
EPCs, tubular formation analysis was performed. In this study,
SCF was selected as a positive control group for neovascular-
ization. The results show that SCF significantly induced neo-
vasculogenesis (Fig. 1B). In comparison with the untreated
control subgroup, SCF at concentrations of 10 and 20 ng/mL
significantly induced neovasculogenesis of EPCs up to 1.36-
and 1.42-fold, respectively (P < 0.05). Treatment with SAC
also significantly induced neovasculogenesis of EPCs in vitro
(Fig. 1B; P < 0.05). Compared to the control group, SAC at
concentrations of 10, 100, and 250 mM significantly increased
neovasculogenesis by approximately 1.2-, 1.3-, and 1.39-fold
(P < 0.05), respectively. The results show that SAC effectively
induced neovasculogenesis of EPCs in vitro.
SAC Modulates Neovasculogenesis through PI3-K/Akt/
eNOS Signaling Pathways in EPCs
We used various inhibitors of the PI3-K and eNOS proteins
to examine the relevant signaling cascades involved in the
molecular mechanisms underlying the SAC-mediated aug-
mentation of neovascularization in EPCs. As shown in
Fig. 2A, treatment with SAC alone (treatment subgroup;
panel b) significantly induced the neovasculogenesis of
EPCs compared to the untreated subgroup (Fig. 2A, panel
a). Moreover, treatments with wortmannin (a PI3-K inhibi-
tor; panel d) or L-NAME (an eNOS inhibitor; panel f) sig-
nificantly inhibited SAC-mediated neovasculogenesis in
EPCs (P < 0.05). Compared to the SAC-treated subgroup
(panel b), L-NAME (0.3 mM) inhibited SAC-mediated neo-
vasculogenesis up to 25%. Wortmannin (10 mM), on the
other hand, inhibited SAC-mediated neovasculogenesis up
to levels as high as 71% that of the SAC-treated subgroup.
However, wortmannin alone (panel c), but not L-NAME
alone (panel e), significantly inhibited neovasculogenesis
in EPCs (Fig. 2B). Neither wortmannin nor L-NAME had
any cytotoxic effects on EPCs (Fig. 2C). These results sug-
gest the PI3-K/Akt/eNOS signaling pathways are involved in
SAC-mediated neovasculogenesis. The inhibitory effects of
wortmannin and L-NAME on neovasculogenesis were not
due to cytotoxic effects.
SAC Augmented c-Kit Expression and Induced
Phosphorylation of the Akt/eNOS Signaling
Proteins in EPCs
As shown in Fig. 3, SAC significantly augmented c-kit pro-
tein expression (P < 0.05). Furthermore, SAC significantly
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enhanced the phosphorylation of the Akt protein and down-
stream target molecules such as GSK-3b and eNOS proteins
in EPCs (P < 0.05). These results suggest that the SAC-
mediated phosphorylation levels (i.e., activation) of the Akt,
eNOS, and GSK-3b proteins are dependent on upregulation
of c-kit protein expression.
SAC Upregulated the Expression of Nuclear b-catenin,
Cyclin D1, and CDK4 Proteins in EPCs
We examined whether SAC regulated the downstream
nuclear proteins in EPCs to further investigate the mechan-
isms of action underlying the effect of SAC. As shown in
Fig. 4, SAC significantly induced the expression of b-cate-
nin, cyclin D1, and CDK4 proteins in EPCs. These results
are in agreement with the previously reported evidence44
and suggest that the SAC-mediated phosphorylation of
GSK-3b contributes to the upregulation of b-catenin and
cyclin D1 proteins in EPCs. Therefore, these results sug-
gested that SAC functions as a neovasculogenic phyto-
chemical, in part, through an upregulation of b-catenin,
cyclin D1, and CDK4 proteins.
SAC Consumption Induced the Neovasculogenesis and
Increased c-Kit Protein Level in Animal Models
To investigate the conclusion drawn from our in vitro results,
we further examined whether SAC consumption would
induce neovasculogenesis in mice. In the xenograft model
of neovasculogenesis, mice were given SAC (0.2 or 2 mg/kg
of BW per day) for 2 wk. The control group received ddH20
without SAC. As in the case of the in vitro EPC study above,
the SCF-treated mice were used as the positive control sub-
group for neovascularization (Fig. 5A, B). SAC consumption
(2 mg/kg of BW per day) significantly augmented the neo-
vascularization in the EPC-inoculated mouse model of neo-
vasculogenesis. Moreover, SAC consumption significantly
increased the amount of c-kit expressing EPCs in the experi-
mental animals (Fig. 5C). These results demonstrate that
SAC consumption is able to increase c-kit expression and
neovascularization in a mouse xenograft model. Taken
together, these results support the notion that SAC consump-
tion induces an increase in the c-kit protein level and EPC-
mediated neovascularization in experimental animals. No
hepatotoxicity was observed in any of the mice receiving
SAC at either 0.2 or 2 mg/kg of BW (Fig. 5D).
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Fig. 2. S-allylcysteine (SAC) modulates neovasculogenesis through PI3-K/Akt/endothelial nitric oxide synthase signaling pathways in
endothelial progenitor cells (EPCs). (A) EPCs were treated with wortmannin (10 mM; panel c, d) or L-NAME (0.3 mM; panel e, f) in the
absence or presence of 100 mM of SAC until the analysis of neovascularization for 8 h, respectively. (B) The values (mean + standard
deviation [SD]) are represented as neovasculogenesis index (folds of tube formation in comparison with the untreated control group) in 8
randomly selected fields in each culture dish. A different letter represents a statistically significant difference among different subgroups (P <
0.05). (C) Cell viability was measured by using 3-[4,5-dimethhylthiaoly]-2,5-diphenyltetrazolium bromide analysis. The proliferation index is
represented as the mean + SD. No significant difference was found (P > 0.05).
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SAC Consumption Exerted Protective Effects
against Ischemic Injury via an Augmentation
of Neovascularization and Collateral Blood
Flow Recovery in Mice
Finally, we examined whether SAC would augment recov-
ery from ischemic injuries through neovasculogenesis in an
ischemic animal model. A mouse model of ischemic injury
was performed by ischemic microsurgery of the unilateral
hind limb in C57/BL mice (n ¼ 6 for each subgroup). Mice
were divided into a control subgroup with ddH2O feeding
only and experimental subgroups with SAC feeding by
gavage at 0.2 mg/kg (low SAC) and 2 mg/kg (high SAC)
of BW/per day. As shown in Fig. 6A, the control mice exhib-
ited slow blood flow recovery after ischemic microsurgery
as shown by laser Doppler imaging. SAC consumption (at
dosages of 0.2 or 2 mg/kg of BW per day) significantly
improved blood flow recovery in ischemic surgery mice. The
effect in the high SAC (2 mg/kg of BW) seemed to be more
effective than the low SAC subgroup (0.2 mg/kg of BW) on
the augmentation of blood flow recovery in ischemic tissues
(P < 0.05; Fig. 6B). Immunofluorescent staining indicated
that both the low SAC and high SAC subgroups displayed
significantly increased c-kit expression in vivo (Fig. 6C).
The quantitative results demonstrated that the low SAC and
high SAC subgroups both exhibited a significantly augmen-
ted c-kit protein level in the mice with ischemic injuries (Fig.
6D). SAC consumption, however, did not have any signifi-
cant effects on VE-cadherin expression (P > 0.05; Fig. 6C,
D). The results showed that SAC consumption (at a dosage
of 0.2 and 2 mg/kg of BW) significantly enhanced the
expression of c-kit protein in ischemic tissues. This suggests
that SAC is a potential therapeutic agent for neovasculogen-
esis by its effect on the upregulation of c-kit and assistance
given to EPCs to make them better able to migrate naturally
into the sites of blood vessels during an ischemic event in
vivo.
Discussion
Ischemic injury is an important risk factor for CLI and CAD.
Neovascularization in the course of ischemic injury plays a
central role in the repair of tissue damage caused by stroke
and heart disease. Unlike the case with EPCs, the proliferation
and migration of mature ECs result in postnatal angiogenesis
from preexisting microcapillaries, thus limiting their potential
for tissue repair.45 Human hematopoietic EPCs derived from
BM, on the other hand, represent a provasculogenic subpopu-
lation that possesses certain critically important characteris-
tics needed for tissue regeneration, such as excellent repair
capability and postnatal neovascularization.
These human EPCs are not only similar to angioblasts but
also have the potential to differentiate readily into ECs.24
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Fig. 3. S-allylcysteine (SAC) augmented c-kit expression and
induced phosphorylation of the Akt/endothelial nitric oxide
synthase (eNOS) signaling proteins in endothelial progenitor cells
(EPCs). EPCs were treated with SAC (10, 100, and 250 mM). Cyto-
plasmic proteins were measured for the detection of c-kit, p-Akt, t-
Akt, p-GSK-3b, t-GSK-3b, p-eNOS, t-eNOS, and actin proteins by
using Western blotting analysis. The levels of detection repre-
sented the total protein of c-kit or the phosphorylation level of
Akt, GSK-3b, and eNOS proteins in the cytoplasm fractions in
triplicate. The integrated densities of these proteins were analyzed
using image analysis software (BioRad Inc.) and adjusted with the
corresponding control proteins such as actin, t-Akt, t-GSK-3b, and
t-eNOS, respectively. Histone H3 nuclear protein was used as a
negative internal control. The asterisk represents a statistically sig-
nificant difference comparing to control subgroup (P < 0.05).
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Fig. 4. S-allylcysteine (SAC) upregulated the expression of nuclear
b-catenin, cyclin D1, and CDK4 proteins in endothelial progenitor
cells (EPCs). EPCs were treated with SAC (10, 100, and 250 mM)
for 8 h. Nuclear proteins were detected for b-catenin, cyclin D1,
CDK4, and lamin A by usingWestern blotting analysis. The levels of
measurement represented the amounts of b-catenin, cyclin D1, and
CDK4 in the nuclei of EPCs. The integrated densities of the b-
catenin, cyclin D1, and CDK4 proteins were analyzed using image
analysis software (BioRad Inc.) and adjusted with the internal con-
trol lamin A protein. The asterisk represents a statistically signifi-
cant difference compared to control subgroup (P < 0.05).
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Fig. 5. S-allylcysteine (SAC) consumption induced the neovasculogenesis and increased c-kit protein level in animal models. To develop a
negative control subgroup, endothelial progenitor cells (EPCs) alone were transplanted into the nude mice. For the positive control
subgroup, EPCs were mixed with stem cell factor (SCF; 20 ng/mL) and subcutaneously inoculated into mice. For the experimental
subgroups, nude mice were inoculated with EPCs and received low dosage (low SAC; 0.2 mg/kg of body weight [BW] per day) or high
dosage (high SAC; 2 mg/kg of BW per day) of SAC by gavage (oral tube feeding) for 2 wk. The neovascularization samples from experimental
animals were sectioned and treated with anti-c-kit antibody by immunohistochemistry staining. Imaging was documented at 200 (A) and
400 (B) magnification. Intense dark brown indicates the distribution of c-kit protein during neovasculogenesis. The formation of vascular
vessel was indicated with a yellow arrow. EPCs were indicated with a blue arrow. The quantitative results (mean+ standard deviation) of
the c-kitþ expressing cells were analyzed by using1-way analysis of variance and shown in the bottom panel (C). Different letters indicate a
significant difference among different subgroups (P < 0.05). Hematoxylin and eosin staining of liver tissues was observed and documented at
200 (D) and 400 (E) magnification in any of the mice receiving SCF (20 ng/mL) or SAC (either 0.2 or 2 mg/kg of BW).
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Numerous studies have shown an inverse relationship
between EPCs and CAD.46 Several clinically approved
drugs have been demonstrated to lower the risk of ischemic
injury and CAD through an augmentation of circulating
EPCs.47 However, there are only a few published studies
suggesting that dietary factors are able to prevent ischemic
injuries and/or CAD.29,38 Our previous studies suggested
that organosulfides such as DADS- and DATS-augmented
neovasculogenesis in vitro.38 In this study, we report the first
evidence that SAC acts as an agent for modulating the induc-
tion of c-kit-expressing EPCs and hence the augmentation of
neovasculogenesis. Here, the results suggest that SAC pre-
vents ischemic injuries by increased blood flow recovery.
Our in vitro results indicate that the neovasculogenic effects
of SAC are comparable to those produced by SCF in EPCs
(Fig. 1B). The molecular mechanisms of action underlying
the effects of SAC were demonstrated using specific inhibi-
tors against signaling molecules such as Akt and eNOS pro-
teins (Fig. 2). In this study, the results also suggested that
SAC induced the neovasculogenesis by modulation of the
Akt/eNOS and GSK-3b signaling cascades (Fig. 3). Several
mechanisms might account for the neovasculogenic effects
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Fig. 6. S-allylcysteine (SAC) consumption exerted protective effects against ischemic injury via an augmentation of neovascularization and
collateral blood flow recovery in mice. (A) On the day of operation procedure (OP), mice received the Doppler imaging scanning right
before and after the vessel-removal surgery. Experimental mice were given ddH2O, low dosage (low SAC; 0.2 mg/kg of body weight [BW]
per day) and high dosage (high SAC; 2 mg/kg of BW per day) of SAC by gavage (oral tube feeding) for 2 wk after receiving the OP. During the
experiment, these C57BL mice received the scheduled scanning by Doppler imaging every day. Quantitative results of blood flow recovery
by Doppler imaging were shown in the bottom panel (B). Different letters indicate a significant difference at each stage (P < 0.05). (C) Green
fluorescence indicates the distribution of VE-cadherin protein stained with the monoclonal antibody (indicted with yellow arrowhead). Red
fluorescence indicates the distribution of c-kit protein stained with the monoclonal antibody (indicted with white arrowhead). Yellow
fluorescence indicates the codistribution of VE-cadherin/c-kit proteins in neovasculogenesis sites (indicted with orange arrowhead). The
blue area represents the location of cell nuclei. Imaging was documented at 600magnification. (D) The values (mean+ standard deviation)
represented the expression of c-kit or VE-cadherin proteins in the bottom panels. Different uppercase letters represent a significant
difference of c-kit expression among different subgroups (P < 0.05). The same lowercase letter represents a nonsignificant difference of
VE-cadherin expression among different subgroups (P > 0.05). The intensity of fluorescence was quantified by Image-Pro Plus version 6.0
software (Media Cybernetics, Rockville, MD).
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of SAC in vitro. One is the augmented phosphorylation of
eNOS in EPCs. Studies have shown that the phosphorylation
of eNOS leads to increased cell migration and neovasculo-
genesis.48 A previous study suggested that SAC might be
involved the reduction of oxidative stress in the atherogenic
process.40 Although we did not test the antioxidant effects of
SAC on neovasculogenesis, the results do suggest an alter-
native mechanism for neovasculogenesis. This study showed
that the beneficial effects of SAC on revascularization of
vascular endothelium take place through the activation of
the Akt/eNOS signaling cascades. Another study reported
that e-NOS/NO may play important roles in the prevention
of CVD.31 Activation of eNOS proteins has been reported to
reduce the senescence of EPCs.49 Moreover, SAC appears to
prevent myocardial injury by activating eNOS and increas-
ing NO metabolites in the vascular system.50,51 These find-
ings are consistent with previous research and support the
cardioprotective effects of garlic extracts on the prevention
of ischemic injury.
In this study, we provide the first evidence for SAC-
induced, EPC-mediated neovascularization. The results
show that SAC upregulated c-kit protein expression and
increased the activation of the PI3-K/Akt/eNOS signaling
cascades. Blocking Akt and eNOS activities with corre-
sponding inhibitors caused a reduction of neovasculogenesis
in EPCs. Thus, the augmented expression of c-kit and acti-
vation of Akt/eNOS cascades play central roles in the
mechanisms of SAC-mediated neovasculogenesis.
Furthermore, the results also indicated that SAC modu-
lated the phosphorylation of multiple signaling molecules
such as Akt/GSK-3b (Fig. 3). Activation of the Akt pathway
resulted in the phosphorylation of GSK3b and led to a
reduced phosphorylation level of b-catenin. This might lead
to the nuclear translocation of b-catenin. This in turn would
upregulate the expression of cyclin D1 and enhance the cell
proliferation of EPCs (Fig. 4). This suggests that SAC
induced the cell proliferation of EPCs and neovasculogen-
esis in part through an upregulation of c-kit protein as well as
b-catenin and the cyclin D1 proteins.
A mouse xenograft study of neovasculogenesis was uti-
lized to further investigate the in vitro results. SAC enhanced
the formation of new blood vessel derived from EPCs (Fig.
5). Furthermore, SAC consumption significantly augmented
the c-kit protein expression in these experimental animals.
At a dosage of 0.2 or 2 mg/kg of BW per day, SAC signif-
icantly induced c-kit protein expression compared with that
of the control subgroup (Fig. 5). Moreover, the results
showed that consumption of SAC improved blood flow
recovery and prevented damage in an ischemic injury animal
model (Fig. 6). Taken together, SAC consumption at a dose
of 0.2 or 2 mg/kg of BW per day in mice is sufficient to
prevent ischemic injuries. It is plausible that SAC consump-
tion alone augments the transplantation effects or enhances
the endogenous activity of EPCs. These results suggest that
SAC alone or used in cotreatment with EPC transplantation
may help prevent ischemic injury and CAD in clinical
applications. Due to the complexity of whole food, it is not
accessible to investigate the molecular mechanisms of crude
garlic extracts on the prevention of ischemic injury. How-
ever, it will be worthy to investigate the preventive applica-
tion of garlic consumption on the prevention of ischemic
injury in further clinical study.
To the best of our knowledge, this is the first evidence
showing that SAC, an active organosulfur compound derived
from AGE, functions as an effective bioactive phytochem-
ical in the induction of neovasculogenesis, and the preven-
tion of ischemic injuries both in vitro and in vivo.
It is possible that the SAC contained in AGE contributes
to the neovasculogenesis of EPCs and the prevention of
ischemic injury, although more research is needed to con-
firm this.
In conclusion, SAC has the potential as a novel neovas-
culogenic agent that improves blood flow recovery and helps
prevent damage from ischemic injuries.
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